



## Dafiro HCT

### Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IG/1098	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	29/04/2019	n/a		
A31/0070	The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing	31/01/2019	11/04/2019	Annex II	Please refer to the assessment report: Dafiro HCT EMEA/H/A-31/1471/C/1160/0070

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.</p> <p>During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan).</p>				
IG/1056	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	11/02/2019	n/a		
N/0075	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/02/2019		PL	
IG/1017	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	11/12/2018	11/04/2019	SmPC and PL	
IG/0986	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/10/2018	11/04/2019	Annex II, Labelling and PL	
IG/0975/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph.</p>	10/09/2018	n/a		

	Eur. Monograph - New certificate from an already approved manufacturer				
T/0068	Transfer of Marketing Authorisation	16/05/2018	25/06/2018	SmPC, Labelling and PL	
IG/0947	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	21/06/2018	n/a		
IG/0910	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	17/04/2018	25/06/2018	SmPC and PL	
IG/0913	B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits	26/03/2018	n/a		
WS/1291/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.  B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method  B.I.b.1.c - Change in the specification parameters	15/03/2018	n/a		

<p>and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p>				
---	--	--	--	--

	<p>material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
IG/0863	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	01/12/2017	n/a		
IG/0826	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	03/08/2017	n/a		
IG/0817/G	<p>This was an application for a group of variations.</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished</p>	28/07/2017	n/a		

	<p>product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised</p> <p>B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised</p>				
IG/0805	A.7 - Administrative change - Deletion of manufacturing sites	23/05/2017	n/a		
PSUSA/10344 /201606	Periodic Safety Update EU Single assessment - amlodipine / valsartan, amlodipine / hydrochlorothiazide / valsartan	09/03/2017	n/a		PRAC Recommendation - maintenance
IG/0776	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	23/02/2017	n/a		
WS/1080	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and</p>	23/02/2017	30/01/2018	SmPC and PL	

	Veterinary Medicinal Products - Other variation				
IG/0733/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>	26/09/2016	n/a		
IG/0727/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	14/09/2016	n/a		
IG/0707	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -	21/07/2016	n/a		

	Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place				
IG/0706	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	21/07/2016	n/a		
N/0053	Update of the package leaflet with revised contact details of the local representative for Germany.  Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/04/2016	30/01/2018	PL	
WS/0704	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.  B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	17/12/2015	n/a		
IG/0585/G	This was an application for a group of variations.  A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)  A.7 - Administrative change - Deletion of	06/07/2015	n/a		



	<p>manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p>				
WS/0710	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Changes related to the amlodipine component</p> <p>Update of section 4.2 of the SmPC to include revised dosing recommendations in patients with hepatic impairment and in elderly patients.</p> <p>Changes related to the valsartan component</p> <p>Update of section 4.8 of the SmPC to update the Preferred Term as per MedDRA version 17.</p> <p>The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and the Package Leaflet.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	26/03/2015	05/05/2015	SmPC and PL	The posology section is updated to highlight that when switching eligible hypertensive patients with hepatic impairment or elderly hypertensive patients to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
IG/0539	<p>C.I.1.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a Union referral procedure - The product is not covered by the defined scope of the procedure</p>	27/03/2015	07/04/2016	SmPC and PL	

IG/0532/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	26/02/2015	n/a		
IG/0528/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>	17/02/2015	n/a		

IG/0527	A.1 - Administrative change - Change in the name and/or address of the MAH	17/02/2015	05/05/2015	SmPC, Labelling and PL	
WS/0616/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	18/12/2014	n/a		
WS/0634/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Replacement of 2 test methods for an active substance intermediate.</p> <p>To include a minor change in a test method for an</p>	23/10/2014	n/a		

	<p>active substance intermediate.</p> <p>To add 3 test methods for an active substance intermediate.</p> <p>To change the specification parameter for an active substance intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters</p>				
--	---	--	--	--	--

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
WS/0636/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>To implement changes in the manufacturing process of the active substance.</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation  B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation  B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS  B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS  B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation  B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method  B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation  B.I.a.2.z - Changes in the manufacturing process of</p>	23/10/2014	n/a		To implement changes in the manufacturing process of the active substance

	<p>the AS - Other variation</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>				
WS/0633/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>To replace 3 test methods for an active substance intermediate.</p> <p>To include a minor change to an approved test procedure for an active substance intermediate.</p> <p>To add a test method or an active substance intermediate.</p> <p>To add 2 alternative test methods for an active substance intermediate.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its</p>	23/10/2014	n/a		

	<p>corresponding test method</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>				
WS/0635/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>To add an alternative manufacturer of AS intermediates.</p> <p>To increase the batch sizes for AS intermediates for the new manufacturing site</p> <p>To delete a manufacturing site for AS intermediates.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other</p>	23/10/2014	n/a		

	<p>variation</p> <p>B.1.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>				
A31/0030	<p>On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit-risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.</p>	22/05/2014	04/09/2014	SmPC and PL	<p>For further information please refer to the Renin-angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report.</p>
R/0038	<p>Renewal of the marketing authorisation.</p>	25/04/2014	04/07/2014	SmPC and PL	<p>Dafiro HCT is a fixed dose combination (FDC) medicinal product containing amlodipine, a dihydropyridine derivative, valsartan, an angiotensin II antagonist and hydrochlorothiazide, a well-known thiazide diuretic. Exforge HCT is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of</p>



					amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. The efficacy data collected since the initial MAA on the combination of amlodipine/ valsartan/ HCTZ remain in accordance with the previous cumulative experience and the efficacy information presented in the Summary of Product Characteristics (SmPC). The safety data remain in accordance with the previous cumulative experience described in the PSURs and the safety information presented in the Core Data Sheet (CDS). The overall evaluation was that the product benefit/risk profile remains positive.
WS/0517	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC to include the ADR 'bullous dermatitis'.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	20/03/2014	04/07/2014	SmPC	The MAH has submitted a comprehensive report with the purpose of reviewing the potential association of skin events with valsartan containing medications, including Exforge and Exforge HCT and respective clones. It is considered justified to update the list of ADRs in section 4.8 'undesirable effects' of the Exforge SmPC and Exforge HCT SmPC and their respective clones based on additional information from a small number of post-marketing cases reporting bullous rash occurring with valsartan. This amendment does not change the benefit risk balance for these products which remains positive.
WS/0508/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>- change in the specification limits of some intermediates used in the manufacture of the active substance, - addition of a new specification parameters with their</p>	20/02/2014	n/a		

<p>corresponding test methods to the specification of some intermediates used in the manufacture of the active substance and</p> <p>- change in test procedures for some intermediates used in the manufacture of the active substance.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
---	--	--	--	--

	<p>B.1.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.1.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.1.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.1.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>				
IG/0400	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	20/01/2014	n/a		
IG/0390/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.1.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for</p>	12/12/2013	n/a		

	<p>the AS -replacement or addition of a site where batch control/testing takes place</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>				
IG/0376/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>	22/11/2013	n/a		
WS/0460	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.5 of the SmPC to include further information regarding an interaction between valsartan and lithium.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	21/11/2013	04/07/2014	SmPC	<p>The MAH has reviewed the clinical databases of four large outcomes studies (Val-HeFT, Value, Valiant, and Navigator) for adverse event reports of lithium toxicity. Further, the Novartis Safety Database (ARGUS) was searched for all cases where both valsartan and lithium were reported as co-administered, and a literature search was performed for published studies.</p> <p>The available data suggest a possible reversible interaction between valsartan and lithium, although the exact mechanism has not been established. The data identified are limited and no confirmatory evidence was available from the clinical trials performed.</p>

					The SmPC has been updated to inform prescribers of the fact that reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with valsartan. Therefore, careful monitoring of serum lithium concentrations is recommended during concomitant use.
IG/0355	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	30/09/2013	n/a		
IG/0349	B.III.1.a.4 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Deletion of certificates (in case multiple certificates exist per material)	27/08/2013	n/a		
WS/0359	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of SmPC sections 4.2, 4.3, 4.4 and 4.5 to reflect that the concomitant use of Angiotensin II Receptor Blockers (ARBs) or Angiotensin-Converting-Enzyme inhibitors (ACEi) with aliskiren is contraindicated in patients with renal impairment and in patients with diabetes mellitus. Further, section 4.4 of the SmPC has been updated to inform prescribers that caution is required, and</p>	27/06/2013	31/07/2013	SmPC, Annex II, Labelling and PL	Please refer to the Scientific Discussion "Exforge HCT-Dafiro HCT-Copalia HCT-EMA-H-C-xxxx-WS-359-AR".

	<p>monitoring of blood pressure, renal function and electrolytes is recommended, when co-administering agents acting on the renin angiotensin aldosterone system (RAAS) i.e. ACEi, ARBs or aliskiren as a direct renin inhibitor. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the SmPC, Annex II and the Package Leaflet in line with the latest QRD template, to implement minor editorial changes in the labelling and Package Leaflet and to add the contact details of the Croatian local representative in the Package Leaflet.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				
IG/0269/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	22/02/2013	n/a		
IG/0248	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/12/2012	n/a		
WS/0333/G	This was an application for a group of variations following a worksharing procedure according to Article	13/12/2012	n/a		

20 of Commission Regulation (EC) No 1234/2008.

To change the specifications and test procedures for hydrochlorothiazide (the active substance) and for an intermediate used in the manufacture of the active substance hydrochlorothiazide.

B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits

B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits

B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method

B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test

	<p>procedure is already authorised</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
IG/0233	B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur.	13/11/2012	n/a		



	Monograph - Updated certificate from an already approved manufacturer				
WS/0252/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>WS-0252-G was a group of variations consisting of two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008 as follows:</p> <p>Variation 1: Update of section 4.4 of the SmPC to add a new warning regarding the risk of 'angioedema' related to the valsartan compound. Further, the MAH took the opportunity to update the wording of the existing warnings in section 4.4 of the SmPC ('renal artery stenosis', 'heart failure', and 'aortic and mitral valve stenosis') for increased clarity. The Package Leaflet has been updated accordingly;</p> <p>Variation 2: Update of sections 4.2, 4.3, 4.4, 4.7, 4.8, 5.1 and 5.2 of the SmPC to harmonise the existing wording related to the amlodipine compound in line with the latest SmPC of Norvasc (amlodipine monotherapy) approved as part of a recent article 30 procedure EMEA/H/A-30/1288. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details for the local representative for Malta in the Package Leaflet.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical,</p>	20/09/2012	31/10/2012	SmPC and PL	<p>The safety update of the SmPC and Package Leaflet was based on a review of the MAH's safety and clinical trial data bases, published literature for both the amlodipine and valsartan components, a recommendation by the US FDA as well as the recent revised and harmonised amlodipine monotherapy (Norvasc) product information that was agreed by the CHMP as part of the article 30 referral procedure EMEA/H/A-30/1288 on 21 July 2011.</p> <p>The MAH presented an extensive analysis of both 'angioedema requiring intubation' and 'previous angioedema with or without ACE-inhibitor use', based on data from their safety database and the clinical trial database. In addition, the MAH provided the outcome of a literature search. From the safety database, 42 patients out of 1469 'angioedema' reports (2.86%) required intubation. In the clinical trial database there was a small number of patients with angioedema who also experienced an AE related to 'respiratory distress' (e.g. laryngospasm, endotracheal intubation, laryngeal edema, mechanical ventilation, tracheostomy, respiratory distress, wheezing).</p> <p>The percentage of patients with a past history of angioedema across all studies was small. A total of 86 patients out of the 1469 reports from the safety database had a previous episode of angioedema, in 40 of these the previous angioedema episode was associated with the use of an ACE-inhibitor and in 46 patients it was not. In 5/40 and 12/46 cases, respectively, the index event was worse than the previous one. This does not indicate that a more severe angioedema event than that occurring in association with an</p>

	<p>clinical or pharmacovigilance data</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				<p>ACE-inhibitor must necessarily be expected when valsartan is given for treatment subsequently.</p> <p>According to the literature, the frequency of angioedema associated with ARBs seems lower than that observed with ACE-inhibitors. Although some publications suggest a higher risk of angioedema with ARBs in patients who had already experienced angioedema with ACE-inhibitors, the frequency data reported in the literature are inconsistent. However, as angioedema is a potentially life-threatening and fatal adverse effect, the reviewed literature highlights that ACE-inhibitors or ARBs should be used with caution in patients with any history of this condition.</p> <p>The safety data provided by the MAH is regarded as sufficient in order to justify the proposed warning on 'angioedema' in section 4.4 of the SmPC. It should also be noted that a warning regarding 'angioedema' is already included in the SmPC for Diovan (valsartan monotherapy).</p> <p>Additional changes to the wording of warnings already included in SmPC section 4.4 ("renal artery stenosis", "heart failure" and "aortic and mitral valve stenosis") were also made as part of this procedure in order to provide further clarity to the health care professional.</p> <p>In addition, the MAH took the opportunity to update the amlodipine sections of the SmPC in accordance with the harmonised product information for Norvasc (amlodipine monotherapy).</p>
WS/0250/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>WS-0250-G was a group of variations consisting of</p>	19/07/2012	30/08/2012	SmPC and PL	<p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</p> <p>Concomitant use of amlodipine with strong or moderate</p>

	<p>two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008 as follows:</p> <p>Variation 1: Update of section 4.5 of the SmPC to add information about the potential drug interaction between amlodipine and simvastatin, and update of the existing amlodipine information in section 4.5 in line with the revised drug interactions section for Norvasc (amlodipine monotherapy). The Package Leaflet has been updated accordingly;</p> <p>Variation 2: Update of section 4.5 of the SmPC to add information about the potential drug interaction between valsartan and inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir). The Package Leaflet has been updated accordingly.</p> <p>C.1.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p> <p>C.1.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				<p>CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required. There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers. Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</p> <p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p> <p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</p> <p>The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter</p>
--	--	--	--	--	---

					(ritonavir) may increase the systemic exposure to valsartan.
IG/0209/G	<p>This was an application for a group of variations.</p> <p>C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV</p> <p>C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system</p>	17/08/2012	n/a		
WS/0282	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>to add a new specification parameter for impurities in the active substance.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p>	19/07/2012	19/07/2012		
IG/0200/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p>	13/07/2012	n/a		

	<p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p>				
WS/0253/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	24/05/2012	28/06/2012	SmPC	The safety of amlodipine in human pregnancy has not been established. Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour

	<p>WS-0253-G is a group of two variations (one type II &amp; one type IB) following a worksharing procedure as follows:</p> <ul style="list-style-type: none"> <li>- Type II variation: Update of section 4.6 of the SmPC with wording on fertility in line with the SmPC for Diovan (valsartan monotherapy) and 5.3 of the SmPC to implement the changes to the SmPC for Diovan that was approved as part of a recent Article 30 (referral) procedure;</li> <li>- Type IB variation: Update of sections 4.6 and 5.3 of the SmPC to implement the changes to the SmPC for Norvasc (amlodipine monotherapy) that was approved as part of a recent Article 30 (referral) procedure.</li> </ul> <p>C.I.1.b - Change in the SPC, Labelling or PL following a referral procedure - The product is not covered by the defined scope of the referral but the change implements the outcome of the referral and no new additional data are submitted by the MAH</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>				<p>and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg. Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p> <p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m<sup>2</sup> basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p> <p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m<sup>2</sup> basis) was close to the maximum tolerated dose for mice but not for rats.</p> <p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p> <p>* Based on patient weight of 50 kg</p> <p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200</p>
--	---	--	--	--	---

mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For

					therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
WS/0172	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of the safety and pharmacokinetic information in the SmPC related to the hydrochlorothiazide component of the fixed-dose combination. As a consequence, sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH has taken the opportunity to implement editorial changes in the SmPC and Package Leaflet and to update the contact details of the local representatives in the Package Leaflet.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>	24/05/2012	28/06/2012	SmPC and PL	<p>The MAH has undertaken the following in-depth review of the clinical safety and clinical pharmacology information available to date on the HCTZ component of the fixed-dose combination:</p> <p>Review of Esidrex (containing HCTZ, first authorised in Switzerland in 1958, nationally authorised in 39 countries) PSURs 1-6 (1 Oct 1989-31 Dec 2009);</p> <p>Cases/events from the MAHs Global Safety Database (NGSD): NGSD was reviewed cumulatively (cut-off date 13 Apr 2010) for all cases (spontaneous reports including literature reports as well as serious adverse events from clinical trials) to identify any unlisted event clusters for Esidrex. No new unlisted event cluster was identified in the summary tabulation from the safety database search;</p> <p>Literature review: Major drug reference books, including Martindale (HCTZ) and Meyler's side effects (thiazide diuretics), were reviewed for unlisted adverse reactions, and bridging literature searches up to the cut-off date of 13 Apr 2010 were performed as per PSUR search criteria (publication date from the PSUR 6 cut-off date: 31 Dec 2009).</p> <p>As a consequence, sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly.</p> <p>Section 4.4 of the SmPC has been updated to include a new warning on the potential risk of 'acute angle-closure glaucoma' associated with the use of hydrochlorothiazide. Hydrochlorothiazide, a sulphonamide, has been associated</p>



					<p>with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.</p> <p>The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.</p> <p>Further, the following new ADRs have been added to section 4.8 of the SmPC: asthenia, pyrexia, erythema multiforme, aplastic anemia, renal disorder, muscle spasm and acute angle-closure glaucoma.</p>
IG/0190/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	15/06/2012	n/a		

IG/0148/G	<p>This was an application for a group of variations.</p> <p>C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD</p> <p>C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system</p>	22/02/2012	n/a		
IB/0009/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding</p>	11/11/2011	n/a		

	<p>manufacturer for batch release)</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions</p> <p>B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p>				
IG/0088/G	<p>This was an application for a group of variations.</p> <p>C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD</p>	11/07/2011	n/a		

	C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
IG/0073/G	This was an application for a group of variations.  B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS  B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	16/06/2011	n/a		
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	31/05/2011	n/a	PL	
IG/0058	B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	13/04/2011	n/a		
WS/0097	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.  To extend the shelf-life of the finished product from 18 months to 2 years. The MAH has also taken the opportunity to update the Annex II.B with the latest wording as per the October and November 2010 CHMP	17/02/2011	17/03/2011	SmPC and Annex II	

	<p>procedural announcement.</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p>				
WS/0088/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>to change the specification limit for an impurity in the active substance ;</p> <p>to add new test procedures for the active substance</p> <p>to add new specifications in the active substance</p> <p>to delete a test procedure for the active substance.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for</p>	17/02/2011	17/02/2011		

	<p>the AS or a starting material/intermediate</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
IG/0032/G	<p>This was an application for a group of variations.</p> <p>To update the Detailed Description of the Pharmacovigilance System (DDPS) to version 9.0, to include:</p> <ul style="list-style-type: none"> <li>- a change in the deputy of the Qualified Person for Pharmacovigilance (QPPV);</li> <li>- a change in the major contractual arrangements.</li> <li>- administrative changes not impacting the operation of the pharmacovigilance system.</li> </ul> <p>Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement.</p> <p>C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV</p> <p>C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of</p>	21/12/2010	n/a		

	<p>pharmacovigilance obligations and described in the DD</p> <p>C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system</p>				
IB/0007/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS</p>	27/10/2010	n/a		

II/0005	<p>Minor change in the manufacturing process of the active substance valsartan.</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p>	23/09/2010	27/09/2010		
IA/0006/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p>	20/09/2010	n/a		
IB/0003/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.1 - Submission of a new or updated Ph. Eur.</p>	22/06/2010	n/a		



	<p>Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>				
IB/0002/G	This was an application for a group of variations.	22/06/2010	n/a		

	<p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>				
IA/0004	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size	18/06/2010	n/a		
II/0001	<p>Changes to QPPV</p> <p>Update of Summary of Product Characteristics</p> <p>Update of DDPS (Pharmacovigilance)</p>	18/02/2010	23/03/2010	Annex II	